Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) to Post Q1 2024 Earnings of $0.71 Per Share, William Blair Forecasts

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Rating) – Equities research analysts at William Blair issued their Q1 2024 earnings per share (EPS) estimates for Actinium Pharmaceuticals in a note issued to investors on Tuesday, May 16th. William Blair analyst A. Hsieh anticipates that the biotechnology company will post earnings per share of $0.71 for the quarter. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.84) per share. William Blair also issued estimates for Actinium Pharmaceuticals’ Q2 2024 earnings at ($0.68) EPS, Q3 2024 earnings at ($0.69) EPS and Q4 2024 earnings at ($0.68) EPS.

Other research analysts have also recently issued research reports about the company. StockNews.com cut Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, March 24th. Cantor Fitzgerald lifted their price target on Actinium Pharmaceuticals from $26.00 to $27.00 in a report on Tuesday, April 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $53.00 price target on shares of Actinium Pharmaceuticals in a report on Thursday, April 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $33.25.

Actinium Pharmaceuticals Stock Down 0.2 %

Shares of NYSEAMERICAN:ATNM opened at $8.39 on Wednesday. The stock has a market cap of $215.87 million, a price-to-earnings ratio of -6.17 and a beta of 0.38. Actinium Pharmaceuticals has a 12-month low of $4.67 and a 12-month high of $15.12. The business’s 50 day moving average is $10.59 and its 200 day moving average is $10.22.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) last announced its quarterly earnings data on Monday, April 3rd. The biotechnology company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). Actinium Pharmaceuticals had a negative net margin of 2,885.09% and a negative return on equity of 46.38%.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS Group AG grew its position in Actinium Pharmaceuticals by 76.2% during the fourth quarter. UBS Group AG now owns 3,235 shares of the biotechnology company’s stock worth $34,000 after buying an additional 1,399 shares in the last quarter. Rockefeller Capital Management L.P. boosted its holdings in shares of Actinium Pharmaceuticals by 11.3% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 14,331 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,450 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Actinium Pharmaceuticals by 1.1% in the 1st quarter. BlackRock Inc. now owns 230,950 shares of the biotechnology company’s stock worth $1,180,000 after purchasing an additional 2,618 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Actinium Pharmaceuticals by 9.4% in the 4th quarter. Millennium Management LLC now owns 53,780 shares of the biotechnology company’s stock worth $573,000 after purchasing an additional 4,632 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Actinium Pharmaceuticals by 12.5% in the 1st quarter. State Street Corp now owns 63,015 shares of the biotechnology company’s stock worth $322,000 after purchasing an additional 7,023 shares in the last quarter. 11.23% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

(Get Rating)

Actinium Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.